modelR06AX22
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Ebastine | |
| ATC code: | R06AX22 | route: | oral |
| compartments: | 1 | |
| dosage: | 20 | mg |
| volume of distribution: | 2.7 | L |
| clearance: | 6.5 | l/h |
| other parameters in model implementation | ||
Ebastine is a second-generation antihistamine used to treat allergic conditions such as allergic rhinitis and chronic idiopathic urticaria. It inhibits peripheral H1 receptors and has minimal sedative effects. Ebastine is approved in several countries for allergy treatment.
Pharmacokinetics
Pharmacokinetic parameters reported in healthy adult subjects after a single oral dose.
References
Simons, FE (2002). Comparative pharmacology of H1 antihistamines: clinical relevance. The American journal of medicine 113 Suppl 9A 38S–46S. DOI:10.1016/s0002-9343(02)01436-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12517581
Chen, K, & Sun, Y (2025). Development and Optimization of Oral Dissolution Films for Enhanced Delivery of Ebastine-Loaded Solid Lipid Nanoparticles. International journal of nanomedicine 20 6963–6981. DOI:10.2147/IJN.S521504 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40462833
Simons, FE, & Simons, KJ (1999). Clinical pharmacology of new histamine H1 receptor antagonists. Clinical pharmacokinetics 36(5) 329–352. DOI:10.2165/00003088-199936050-00003 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10384858
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)